Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13189585 | 0.82 | NR1H2 (0.45) | NR1H2BRD4ROCK1KDRALDH1A1 | |
| SCHEMBL12728711 | 0.80 | NR1H2 (0.47) | NR1H2BRD4ROCK1PNP | |
| SCHEMBL12728715 | 0.79 | NR1H2 (0.52) | NR1H2BRD4ROCK1KDRPARP1 | |
| SCHEMBL12152965 | 0.79 | NR1H2 (0.43) | NR1H2ROCK1KDR | |
| SCHEMBL2447815 | 0.79 | NR1H2 (0.52) | NR1H2BRD4ROCK1KDRMAP2K1 | |
| SCHEMBL12330551 | 0.78 | NR1H2 (0.48) | NR1H2BRD4ROCK1 | |
| SCHEMBL4049732 | 0.78 | NR1H2 (0.42) | NR1H2BRD4ROCK1PARP1 | |
| SCHEMBL12728712 | 0.77 | NR1H2 (0.41) | NR1H2BRD4ROCK1PARP1 | |
| SCHEMBL14017246 | 0.76 | NR1H2 (0.43) | NR1H2BRD4 | |
| SCHEMBL2446434 | 0.75 | NR1H2 (0.55) | NR1H2ROCK1KDRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| EP-2010538-B1 | PROCESS FOR THE PREPARATION OF Ý(1R), 2S¨-2-AMINOPROPIONIC ACID 2-Ý4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLOÝ2,1-f¨Ý1,2,4¨TRIAZIN-6-YLOXY¨-1-METHYLETHYL ESTER | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7671199-B2 | Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester | BRITSOL-MYERS SQUIBB COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671199-B2 | Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester | BRITSOL-MYERS SQUIBB COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1960403-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1960403-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-20050288289-A1 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | NR1H2 3047/4885BRD4 586/4885ROCK1 385/4885 |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | NR1H2 3656/4885BRD4 1722/4885ROCK1 316/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | NR1H2 3656/4885BRD4 1722/4885ROCK1 316/4885 |
| US-20050288289-A1 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | MAP3K15, MAP4K2, MAP3K20 | NR1H2 4331/4885BRD4 801/4885ROCK1 502/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | NR1H2 3177/4885BRD4 513/4885ROCK1 469/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | NR1H2 3047/4885BRD4 586/4885ROCK1 385/4885 |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | MAP3K15, MAP3K5, STK25 | NR1H2 3464/4885BRD4 508/4885ROCK1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.